LBPH
Closed
Longboard Pharmaceuticals Inc
59.98
0.00 (0.00%)
Last Update: 13 Dec 2024 17:30:00
Yesterday: 59.98
Day's Range: 59.98 - 59.98
Send
sign up or login to leave a comment!
When Written:
5.11
Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological diseases. The company was founded in 2018 and is headquartered in Morrisville, North Carolina. Longboard's lead product candidate, LP352, is a small molecule inhibitor of the enzyme phosphodiesterase 4 (PDE4) that is being developed for the treatment of Fragile X Syndrome (FXS). FXS is a genetic disorder that causes intellectual disability, behavioral and emotional problems, and other symptoms. LP352 has demonstrated promising results in preclinical studies and is currently being evaluated in a Phase 1 clinical trial. Longboard is also developing other PDE4 inhibitors for the treatment of other neurological disorders, such as Alzheimer's disease and schizophrenia. The company is backed by leading healthcare investors and has partnerships with academic institutions and other biopharmaceutical companies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








